Introduction
The Danish National Acute Leukemia Registry (DNLR) includes adult patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).
The aim of the registry is to gain insight into the epidemiology of these cancers, to evaluate treatment responses, to compare results between geographical regions of Denmark, and, through research, to identify prognostic and predictive factors for outcome. One ultimate aim is to improve the quality of treatment and care for acute leukemia and MDS patients.
The DNLR has been a part of the Danish Hematological Database since 2005. Reporting of patient data for the aforementioned diagnoses is mandatory, and obtainment of patient consent is not required. Financial support for the registry depends directly on 
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Østgård et al registration completeness and coverage. The steering committee for the registry is required to publish an annual report based on specific quality indicators. The indicators are data completeness; 30-, 180-day, 1-, 3-, and 5-year mortality; time from diagnosis to treatment initiation (TTT); and proportions of patients achieving a complete remission (CR), included in clinical trials, and with a cytogenetic evaluation at diagnosis. 1 
Study population
Acute leukemias are highly aggressive blood cancers, arising from hematopoietic stem cells or committed progenitor cells.
The acute leukemia is classified as myeloid or lymphoblastic leukemia (AML or ALL) depending on origin. Both AML and ALL are characterized by rapid outgrowth of leukemic cells that disrupt the production of normal blood cells. This enhances the risks of anemia, life-threatening infections, and bleeding complications. Prognostic factors, types of treatment, and prognosis differ between the two subtypes. In AML patients, the three most important prognostic factors are age, cytogenetic alterations, and performance status (PS) ( Figure 1A and B) . 2 The survival in younger ALL patients has improved over time, but despite the development of 
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The Danish National Acute Leukemia Registry new treatment regimens for AML, survival rates for AML patients have not changed significantly over more than a decade ( Figure 1C and D) . MDS also arises from myeloid stem cells or committed progenitor cells, and is associated with ineffective production and dysfunction of the normal blood cells. The spectrum of MDS ranges from light anemia to affecting all the three hematopoietic cell lines. 2 Treatment principles vary from supportive care only (use of blood products, antibiotics, and growth factors), to low-dose chemotherapy, and to intensive AML-like remission-inducing chemotherapy in patients with increasing blast counts progressing to AML. Overall survival and time to progression to AML can be estimated using the original or revised International Prognostic Scoring System. 
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Østgård et al specialized hematological departments. Six of these departments offer intensive therapy to AML and ALL patients, though treatment of Philadelphia chromosome-negative ALL patients younger than 45 years is centralized at three centers. MDS patients are treated at all ten departments. Two centers perform allogeneic hematopoietic stem cell transplantation in ALL, AML, and MDS patients. The Danish Society of Hematology established the DNLR in 2000. Since then, all adult (.15 years) AML patients diagnosed in Denmark have been recorded. Since January 2005, adult patients diagnosed with ALL have also been included. In 2010, a separate registry for newly diagnosed cases of MDS was established. Before then, only cases of advanced MDS that were treated using AML protocols were recorded in the leukemia registry. 1 Since the beginning of registration, more than 3,500 AML patients, 300 ALL patients, and 1,100 MDS patients diagnosed before January 1, 2015 have been registered in the DNLR. The continuing registration annually expands the registry with ∼250 AML patients, 25 ALL patients, and 230 MDS.
Main variables
The DNLR uses standardized web-based registration forms to collect data and the system allows programmed data entry checks. Lists of patients newly diagnosed with AML, ALL, or MDS in the Danish National Registry of Patients (DNRP) 5 are sent to each hematological department for a confirmation of the diagnosis. If correct, additional data are entered in the registry. For these purposes, medical records including pathology records (Patobank) 6 are used. To ensure high coverage and completeness of data, the registry is linked to the Danish Civil Registration System 7 and the DNRP every 3 months. For AML and ALL patients, up to four registration forms are completed during the disease course of each patient 
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The Danish National Acute Leukemia Registry ( Table 1 ). Depending on treatment schedule and clinical course, data on more than 150 variables (patient-and leukemia-related, treatment-and outcome-related) can be recorded for each patient. The first form is completed at diagnosis. To optimize data quality, the clinical cytogeneticist enters cytogenetic details obtained at diagnosis. A second form is completed following first-line treatment in chemotherapytreated patients and includes information about allogeneic transplantation performed in first CR. A third form is completed in case of relapse. A fourth form is completed at death or termination of clinical follow-up.
For MDS patients, up to three registration forms are completed: a registration form at diagnosis, a treatment form, and a form at death or termination of follow-up.
We recently performed a validation study of the quality of AML registrations in the DNLR. 8 In that study, the coverage of the DNLR was found to be 99.6% (95% confidence interval [CI] 99.3-99.8) with the DNRP used as a reference. We validated DNLR information in a random sample of 260 patients, and found completeness to exceed 90% in 23 out of 30 selected variables. The positive predictive values (PPVs) were higher than 95% for 23 variables, and higher than 90% for 29 of 30 variables ( Table 2 ). The quality of data registered on ALL patients is not expected to vary, since the variables are identical and the same physicians are entering data. The coverage of the MDS registry is estimated to be 90%, and a validation study of the individual variables has been planned for MDS data to be performed prior to use of data for research purposes.
Follow-up
In leukemia patients, treatment responses are registered according to international guidelines. 9 For patients achieving CR, relapses are registered. For all patients, date of death or end of follow-up due to other causes is registered in the DNLR. Data are cross-linked to the Danish Civil Registration System to ensure accurate information on vital status. Based on these variables, leukemia-free and overall survival can be calculated.
Since both ALL and AML are aggressive cancers and MDS patients in general are older, a high proportion of patients die within 1-5 years of follow-up. (Overall survival rates for AML and ALL patients are shown in Figure 1 .) By December 2013, the DNLR consisted of data on 3,055 AML patients (excluding acute promyelocytic leukemia). In September 2014, these 
Examples of research
The DNLR has been used for various studies in which it has been merged with local databases (transplantation and clinical trial office databases) and national registries (the Danish Civil Registration System, DNRP, the Danish Cancer Registry). In one study, the registry was used to investigate the impact of patient and disease characteristics on TTT and to assess the effect of TTT on treatment response (CR) and survival. 10 In a second study, data were used to examine how treatment intent varies by comorbidity and functional status (World Health Organization performance status score [WHO PS]) and to determine the prognostic impact of comorbidity and PS on achievement of CR, early death, and long-term mortality.
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In a third study, data were used to estimate frequencies of therapy-related and secondary AML (MDS and non-MDS) overall and over time; they were also used to describe differences in characteristics, and outcome between intensively treated secondary and therapy-related AML (depending on prior hematological disease or cytotoxic therapy) and de novo AML patients. 12 In a fourth study, the registry was used to estimate the patient accrual rates of clinical AML trials in Denmark, to describe the difference in patient and disease characteristics as well as outcome between patients treated according to clinical trials and those treated outside clinical trials. 13 In an ongoing study, researchers are investigating the impact of body mass index (BMI) on prognosis. Data on smoking and alcohol consumption are obtained from medical records and will be used to investigate the impact of lifestyle factors on outcome.
Finally, the importance of the quality of CR with reconstitution of bone marrow function is being investigated using data from the National Danish Transfusion Database.
ALL and MDS data have not yet been used for research, as the number of patients is relatively small and the followup time is short. A Nordic collaboration aims to merge data between national MDS registries, thereby expanding the study population.
Conclusion
The DNLR includes patient and disease characteristics, as well as outcome data on MDS and acute leukemia patients. The completeness and PPVs of the data are high, and the registry captures more than 99.5% of AML patients. So far, these high-quality data have been used for large nationwide prognostic studies of AML. Within the next 5 years, the follow-up time for MDS and ALL patients will allow these data to be explored. In conclusion, the DNLR has shown to be a valuable resource for clinical research of acute leukemia.
